Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stimulants01:29

Stimulants

Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Findings of Research Misconduct.

Federal register·2026
Same journal

Findings of Research Misconduct.

Federal register·2026
Same journal

Findings of Research Misconduct.

Federal register·2026
Same journal

Findings of Research Misconduct.

Federal register·2025
Same journal

Findings of Research Misconduct.

Federal register·2025
Same journal

Findings of Research Misconduct.

Federal register·2024

Related Experiment Video

Updated: May 31, 2026

Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements
06:39

Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements

Published on: August 28, 2017

Required warnings for cigarette packages and advertisements. Final rule.

    Federal Register
    |June 24, 2011
    PubMed
    Summary

    The Food and Drug Administration (FDA) now requires graphic health warnings on cigarette packs and ads. This rule mandates color images depicting smoking

    Area of Science:

    • Public Health
    • Regulatory Science
    • Tobacco Control

    Background:

    • The Family Smoking Prevention and Tobacco Control Act mandates new warning requirements for tobacco products.
    • Previous regulations lacked impactful visual health warnings on cigarette packaging and advertisements.

    Purpose of the Study:

    • To implement the Tobacco Control Act's requirement for graphic health warnings on cigarettes.
    • To specify the visual elements for new health warnings on tobacco products.

    Main Methods:

    • Amending existing Food and Drug Administration (FDA) regulations.
    • Finalizing color graphic images to accompany mandated textual health warnings.

    Main Results:

    • New regulations require color graphics depicting negative health consequences of smoking.

    More Related Videos

    Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
    09:25

    Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations

    Published on: January 10, 2015

    Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System
    10:44

    Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System

    Published on: May 24, 2017

    Related Experiment Videos

    Last Updated: May 31, 2026

    Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements
    06:39

    Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements

    Published on: August 28, 2017

    Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
    09:25

    Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations

    Published on: January 10, 2015

    Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System
    10:44

    Comparing the Effects of Electronic Cigarette Vapor and Cigarette Smoke in a Novel In Vivo Exposure System

    Published on: May 24, 2017

  • Nine new textual warning statements will be accompanied by specific graphic images.
  • Conclusions:

    • The FDA's final rule enhances tobacco product labeling requirements.
    • Graphic warnings aim to increase public awareness of smoking-related health risks.